{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:05:07Z","timestamp":1786460707744,"version":"build-2736575974"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":69,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Center for High-performance Computing (NCHC) of National Institutes of Applied Research (NIAR) and National Core Facility for Biopharmaceuticals","award":["NCFB 111-2740-B-492-001; NCFB, NSTC 114-2740-B-492-001"],"award-info":[{"award-number":["NCFB 111-2740-B-492-001; NCFB, NSTC 114-2740-B-492-001"]}]},{"name":"National Core Facility for Biopharmaceuticals Pharmacogenomics Lab TR6","award":["MOST 111-2740-B-002-005"],"award-info":[{"award-number":["MOST 111-2740-B-002-005"]}]},{"DOI":"10.13039\/501100010425","name":"Tri-Service General Hospital","doi-asserted-by":"publisher","award":["MOST 105-2314-B-016-041-MY3, MOST 107-2314-B-016-025, and TSGH-C108-126"],"award-info":[{"award-number":["MOST 105-2314-B-016-041-MY3, MOST 107-2314-B-016-025, and TSGH-C108-126"]}],"id":[{"id":"10.13039\/501100010425","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key and Novel Therapeutics Development Program for Major Diseases","award":["AS-KPQ-111-KNT"],"award-info":[{"award-number":["AS-KPQ-111-KNT"]}]},{"name":"Medicinal Chemistry and Analytical Core Facilities","award":["AS-NBRPCF-111-201"],"award-info":[{"award-number":["AS-NBRPCF-111-201"]}]},{"name":"Next-Generation Pathway of Taiwan Cancer Precision Medicine Program","award":["AS-KPQ-107-TCPMP"],"award-info":[{"award-number":["AS-KPQ-107-TCPMP"]}]},{"name":"Academia Sinica Common Mass Spectrometry Facilities","award":["AS-CFII-111-209"],"award-info":[{"award-number":["AS-CFII-111-209"]}]},{"name":"Intelligent Multi-Omics Precision Medicine","award":["AS-KPQ-115-IMPM"],"award-info":[{"award-number":["AS-KPQ-115-IMPM"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-026-02701-x","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:36:13Z","timestamp":1780472173000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Navigating luminal heterogeneity: etiology-based proteogenomic subtyping for targeted treatment strategies in breast cancer"],"prefix":"10.1186","volume":"25","author":[{"given":"Ya-Hsuan","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ju","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Jie","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Jing","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuen-Tyng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Shiou","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Fang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze-Shiang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huei-Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Li","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric Sheng-Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin-Chen","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Chin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Si","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiang-En","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Hung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin-Lian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Shan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Ting","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Tzu","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan-Ni","family":"Hsing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsai-Pei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Tai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Wei","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Hok","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana I","family":"Robles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Show-Ling","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mien-Chie","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Shen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsuan-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Liang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyh-Cherng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ju","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"2701_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"2701_CR2","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1093\/jnci\/djz090","volume":"111","author":"CH Lin","year":"2019","unstructured":"Lin CH, Yap YS, Lee KH, Im SA, Naito Y, Yeo W, et al. Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians vs the US Population. J Natl Cancer Inst. 2019;111:1298\u2013306.","journal-title":"J Natl Cancer Inst"},{"key":"2701_CR3","first-page":"439","volume":"67","author":"CE DeSantis","year":"2017","unstructured":"DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 2017;67:439\u201348.","journal-title":"CA Cancer J Clin"},{"key":"2701_CR4","doi-asserted-by":"crossref","unstructured":"Lei S, Zheng R, Zhang S, Chen R, Wang S, Sun K et al. Breast cancer incidence and mortality in women in China: temporal trends and projections to 2030. Cancer Biol Med 2021.","DOI":"10.20892\/j.issn.2095-3941.2020.0523"},{"key":"2701_CR5","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1158\/1055-9965.EPI-09-0096","volume":"18","author":"CH Lin","year":"2009","unstructured":"Lin CH, Liau JY, Lu YS, Huang CS, Lee WC, Kuo KT, et al. Molecular subtypes of breast cancer emerging in young women in Taiwan: evidence for more than just westernization as a reason for the disease in Asia. Cancer Epidemiol Biomarkers Prev. 2009;18:1807\u201314.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2701_CR6","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1158\/1078-0432.CCR-11-2599","volume":"18","author":"HA Azim Jr","year":"2012","unstructured":"Azim HA Jr., Michiels S, Bedard PL, Singhal SK, Criscitiello C, Ignatiadis M, et al. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res. 2012;18:1341\u201351.","journal-title":"Clin Cancer Res"},{"key":"2701_CR7","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","volume":"385","author":"K Kalinsky","year":"2021","unstructured":"Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, et al. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. N Engl J Med. 2021;385:2336\u201347.","journal-title":"N Engl J Med"},{"key":"2701_CR8","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S1470-2045(21)00007-3","volume":"22","author":"M Piccart","year":"2021","unstructured":"Piccart M, van \u2018t Veer LJ, Poncet C, Lopes Cardozo JMN, Delaloge S, Pierga JY, et al. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Lancet Oncol. 2021;22:476\u201388.","journal-title":"Lancet Oncol"},{"key":"2701_CR9","doi-asserted-by":"publisher","first-page":"5679","DOI":"10.1038\/s41467-020-19342-3","volume":"11","author":"GT Lang","year":"2020","unstructured":"Lang GT, Jiang YZ, Shi JX, Yang F, Li XG, Pei YC, et al. Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing. Nat Commun. 2020;11:5679.","journal-title":"Nat Commun"},{"key":"2701_CR10","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41586-024-08377-x","volume":"638","author":"KE Houlahan","year":"2025","unstructured":"Houlahan KE, Mangiante L, Sotomayor-Vivas C, Adimoelja A, Park S, Khan A, et al. Complex rearrangements fuel ER(+) and HER2(+) breast tumours. Nature. 2025;638:510\u20138.","journal-title":"Nature"},{"key":"2701_CR11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/14789450.2018.1421071","volume":"15","author":"C Mueller","year":"2018","unstructured":"Mueller C, Haymond A, Davis JB, Williams A, Espina V. Protein biomarkers for subtyping breast cancer and implications for future research. Expert Rev Proteom. 2018;15:131\u201352.","journal-title":"Expert Rev Proteom"},{"key":"2701_CR12","first-page":"4006","volume":"11","author":"AN Neagu","year":"2021","unstructured":"Neagu AN, Whitham D, Buonanno E, Jenkins A, Alexa-Stratulat T, Tamba BI, et al. Proteomics and its applications in breast cancer. Am J Cancer Res. 2021;11:4006\u201349.","journal-title":"Am J Cancer Res"},{"key":"2701_CR13","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1038\/s41467-019-09018-y","volume":"10","author":"HJ Johansson","year":"2019","unstructured":"Johansson HJ, Socciarelli F, Vacanti NM, Haugen MH, Zhu Y, Siavelis I, et al. Breast cancer quantitative proteome and proteogenomic landscape. Nat Commun. 2019;10:1600.","journal-title":"Nat Commun"},{"key":"2701_CR14","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.cell.2020.10.036","volume":"183","author":"K Krug","year":"2020","unstructured":"Krug K, Jaehnig EJ, Satpathy S, Blumenberg L, Karpova A, Anurag M, et al. Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy. Cell. 2020;183:1436\u2013e5631.","journal-title":"Cell"},{"key":"2701_CR15","doi-asserted-by":"publisher","first-page":"6276","DOI":"10.1038\/s41467-021-26502-6","volume":"12","author":"BD Lehmann","year":"2021","unstructured":"Lehmann BD, Colaprico A, Silva TC, Chen J, An H, Ban Y, et al. Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes. Nat Commun. 2021;12:6276.","journal-title":"Nat Commun"},{"key":"2701_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nature18003","volume":"534","author":"P Mertins","year":"2016","unstructured":"Mertins P, Mani DR, Ruggles KV, Gillette MA, Clauser KR, Wang P, et al. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature. 2016;534:55\u201362.","journal-title":"Nature"},{"key":"2701_CR17","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1038\/s12276-024-01332-w","volume":"56","author":"KA Yoon","year":"2024","unstructured":"Yoon KA, Kim Y, Jung SY, Ryu JS, Kim KH, Lee EG, et al. Proteogenomic analysis dissects early-onset breast cancer patients with prognostic relevance. Exp Mol Med. 2024;56:2382\u201394.","journal-title":"Exp Mol Med"},{"key":"2701_CR18","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1158\/0008-5472.CAN-24-5002","volume":"85","author":"XZ Zhu","year":"2025","unstructured":"Zhu XZ, Zhang HY, Zhou YF, Chen YY, Fu T, Jin ML, et al. Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+\/HER2- Breast Cancer. Cancer Res. 2025;85:3983\u201398.","journal-title":"Cancer Res"},{"key":"2701_CR19","doi-asserted-by":"crossref","unstructured":"Elfgen C, Bjelic-Radisic V. Targeted Therapy in HR+ HER2- Metastatic Breast Cancer: Current Clinical Trials and Their Implications for CDK4\/6 Inhibitor Therapy and beyond Treatment Options. Cancers (Basel) 2021;13.","DOI":"10.3390\/cancers13235994"},{"key":"2701_CR20","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016;375:1925\u201336.","journal-title":"N Engl J Med"},{"key":"2701_CR21","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.breast.2021.07.002","volume":"59","author":"HF Gao","year":"2021","unstructured":"Gao HF, Lin YY, Zhu T, Ji F, Zhang LL, Yang CQ, et al. Adjuvant CDK4\/6 inhibitors combined with endocrine therapy in HR-positive, HER2-negative early breast cancer: A meta-analysis of randomized clinical trials. Breast. 2021;59:165\u201375.","journal-title":"Breast"},{"key":"2701_CR22","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1158\/2159-8290.CD-15-0894","volume":"6","author":"CJ Sherr","year":"2016","unstructured":"Sherr CJ, Beach D, Shapiro GI. Targeting CDK4 and CDK6: From Discovery to Therapy. Cancer Discov. 2016;6:353\u201367.","journal-title":"Cancer Discov"},{"key":"2701_CR23","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","volume":"27","author":"JS Parker","year":"2009","unstructured":"Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27:1160\u20137.","journal-title":"J Clin Oncol"},{"key":"2701_CR24","doi-asserted-by":"publisher","first-page":"7956","DOI":"10.1038\/s41598-019-44339-4","volume":"9","author":"PK Raj-Kumar","year":"2019","unstructured":"Raj-Kumar PK, Liu J, Hooke JA, Kovatich AJ, Kvecher L, Shriver CD, et al. PCA-PAM50 improves consistency between breast cancer intrinsic and clinical subtyping reclassifying a subset of luminal A tumors as luminal B. Sci Rep. 2019;9:7956.","journal-title":"Sci Rep"},{"key":"2701_CR25","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/s41416-018-0140-8","volume":"119","author":"X Wang","year":"2018","unstructured":"Wang X, Steensma JT, Bailey MH, Feng Q, Padda H, Johnson KJ. Characteristics of The Cancer Genome Atlas cases relative to U.S. general population cancer cases. Br J Cancer. 2018;119:885\u201392.","journal-title":"Br J Cancer"},{"key":"2701_CR26","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.cell.2020.06.012","volume":"182","author":"YJ Chen","year":"2020","unstructured":"Chen YJ, Roumeliotis TI, Chang YH, Chen CT, Han CL, Lin MH, et al. Proteogenomics of Non-smoking Lung Cancer in East Asia Delineates Molecular Signatures of Pathogenesis and Progression. Cell. 2020;182:226\u201344. e17.","journal-title":"Cell"},{"key":"2701_CR27","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1158\/1078-0432.CCR-21-2572","volume":"28","author":"AG Waks","year":"2022","unstructured":"Waks AG, Kim D, Jain E, Snow C, Kirkner GJ, Rosenberg SM, et al. Somatic and Germline Genomic Alterations in Very Young Women with Breast Cancer. Clin Cancer Res. 2022;28:2339\u201348.","journal-title":"Clin Cancer Res"},{"key":"2701_CR28","first-page":"821","volume":"177","author":"JE Kucab","year":"2019","unstructured":"Kucab JE, Zou X, Morganella S, Joel M, Nanda AS, Nagy E, et al. Compendium Mutational Signatures Environ Agents Cell. 2019;177:821\u201336. e16.","journal-title":"Compendium Mutational Signatures Environ Agents Cell"},{"key":"2701_CR29","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415\u201321.","journal-title":"Nature"},{"key":"2701_CR30","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.celrep.2012.12.008","volume":"3","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov LB, Nik-Zainal S, Wedge DC, Campbell PJ, Stratton MR. Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 2013;3:246\u201359.","journal-title":"Cell Rep"},{"key":"2701_CR31","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28:1747\u201356.","journal-title":"Genome Res"},{"key":"2701_CR32","doi-asserted-by":"publisher","first-page":"e0168288","DOI":"10.1371\/journal.pone.0168288","volume":"12","author":"T Strauss","year":"2017","unstructured":"Strauss T, von Maltitz MJ. Generalising Ward\u2019s Method for Use with Manhattan Distances. PLoS ONE. 2017;12:e0168288.","journal-title":"PLoS ONE"},{"key":"2701_CR33","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.envpol.2005.09.025","volume":"142","author":"KF Chang","year":"2006","unstructured":"Chang KF, Fang GC, Chen JC, Wu YS. Atmospheric polycyclic aromatic hydrocarbons (PAHs) in Asia: a review from 1999 to 2004. Environ Pollut. 2006;142:388\u201396.","journal-title":"Environ Pollut"},{"key":"2701_CR34","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1093\/carcin\/bgy058","volume":"39","author":"L Reed","year":"2018","unstructured":"Reed L, Arlt VM, Phillips DH. The role of cytochrome P450 enzymes in carcinogen activation and detoxication: an in vivo-in vitro paradox. Carcinogenesis. 2018;39:851\u20139.","journal-title":"Carcinogenesis"},{"key":"2701_CR35","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.celrep.2015.08.066","volume":"13","author":"M Periyasamy","year":"2015","unstructured":"Periyasamy M, Patel H, Lai CF, Nguyen VTM, Nevedomskaya E, Harrod A, et al. APOBEC3B-Mediated Cytidine Deamination Is Required for Estrogen Receptor Action in Breast Cancer. Cell Rep. 2015;13:108\u201321.","journal-title":"Cell Rep"},{"key":"2701_CR36","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","volume":"19","author":"JJ Havel","year":"2019","unstructured":"Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19:133\u201350.","journal-title":"Nat Rev Cancer"},{"key":"2701_CR37","doi-asserted-by":"publisher","first-page":"e2418318122","DOI":"10.1073\/pnas.2418318122","volume":"122","author":"GB Jin","year":"2025","unstructured":"Jin GB, Rong SQ, Yin DR, Deng ZH, Ding X, Sheng MY, et al. Neomorphic leukemia-derived mutations in the TET2 enzyme induce genome instability via a substrate shift from 5-methylcytosine to thymine. Proc Natl Acad Sci U S A. 2025;122:e2418318122.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2701_CR38","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1080\/15592294.2017.1359452","volume":"12","author":"JB Coulter","year":"2017","unstructured":"Coulter JB, Lopez-Bertoni H, Kuhns KJ, Lee RS, Laterra J, Bressler JP. TET1 deficiency attenuates the DNA damage response and promotes resistance to DNA damaging agents. Epigenetics. 2017;12:854\u201364.","journal-title":"Epigenetics"},{"key":"2701_CR39","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13148-018-0601-1","volume":"11","author":"V Kari","year":"2019","unstructured":"Kari V, Raul SK, Henck JM, Kitz J, Kramer F, Kosinsky RL, et al. The histone methyltransferase DOT1L is required for proper DNA damage response, DNA repair, and modulates chemotherapy responsiveness. Clin Epigenetics. 2019;11:4.","journal-title":"Clin Epigenetics"},{"key":"2701_CR40","doi-asserted-by":"publisher","first-page":"6874","DOI":"10.1038\/s41598-023-33932-3","volume":"13","author":"N Besselink","year":"2023","unstructured":"Besselink N, Keijer J, Vermeulen C, Boymans S, de Ridder J, van Hoeck A, et al. The genome-wide mutational consequences of DNA hypomethylation. Sci Rep. 2023;13:6874.","journal-title":"Sci Rep"},{"key":"2701_CR41","doi-asserted-by":"publisher","first-page":"zcac023","DOI":"10.1093\/narcan\/zcac023","volume":"4","author":"X Hu","year":"2022","unstructured":"Hu X, Biswas A, De S. KMT2C-deficient tumors have elevated APOBEC mutagenesis and genomic instability in multiple cancers. NAR Cancer. 2022;4:zcac023.","journal-title":"NAR Cancer"},{"key":"2701_CR42","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1083\/jcb.200209065","volume":"160","author":"GD Kao","year":"2003","unstructured":"Kao GD, McKenna WG, Guenther MG, Muschel RJ, Lazar MA, Yen TJ. Histone deacetylase 4 interacts with 53BP1 to mediate the DNA damage response. J Cell Biol. 2003;160:1017\u201327.","journal-title":"J Cell Biol"},{"key":"2701_CR43","doi-asserted-by":"publisher","first-page":"5775","DOI":"10.1038\/s41467-020-19502-5","volume":"11","author":"MB Rother","year":"2020","unstructured":"Rother MB, Pellegrino S, Smith R, Gatti M, Meisenberg C, Wiegant WW, et al. CHD7 and 53BP1 regulate distinct pathways for the re-ligation of DNA double-strand breaks. Nat Commun. 2020;11:5775.","journal-title":"Nat Commun"},{"key":"2701_CR44","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","volume":"8","author":"N Xie","year":"2023","unstructured":"Xie N, Shen G, Gao W, Huang Z, Huang C, Fu L. Neoantigens: promising targets for cancer therapy. Signal Transduct Target Ther. 2023;8:9.","journal-title":"Signal Transduct Target Ther"},{"key":"2701_CR45","doi-asserted-by":"publisher","first-page":"824586","DOI":"10.3389\/fimmu.2022.824586","volume":"13","author":"P Zhang","year":"2022","unstructured":"Zhang P, Liu G, Hu J, Chen S, Wang B, Peng P, et al. Tenascin-C can Serve as an Indicator for the Immunosuppressive Microenvironment of Diffuse Low-Grade Gliomas. Front Immunol. 2022;13:824586.","journal-title":"Front Immunol"},{"key":"2701_CR46","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1158\/0008-5472.CAN-14-2346","volume":"75","author":"E Jachetti","year":"2015","unstructured":"Jachetti E, Caputo S, Mazzoleni S, Brambillasca CS, Parigi SM, Grioni M, et al. Tenascin-C Protects Cancer Stem-like Cells from Immune Surveillance by Arresting T-cell Activation. Cancer Res. 2015;75:2095\u2013108.","journal-title":"Cancer Res"},{"key":"2701_CR47","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/s41573-020-0076-6","volume":"19","author":"NJ Curtin","year":"2020","unstructured":"Curtin NJ, Szabo C. Poly(ADP-ribose) polymerase inhibition: past, present and future. Nat Rev Drug Discov. 2020;19:711\u201336.","journal-title":"Nat Rev Drug Discov"},{"key":"2701_CR48","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","volume":"22","author":"ML Telli","year":"2016","unstructured":"Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, et al. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Clin Cancer Res. 2016;22:3764\u201373.","journal-title":"Clin Cancer Res"},{"key":"2701_CR49","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1101\/gad.193193.112","volume":"26","author":"RH Wright","year":"2012","unstructured":"Wright RH, Castellano G, Bonet J, Le Dily F, Font-Mateu J, Ballare C, et al. CDK2-dependent activation of PARP-1 is required for hormonal gene regulation in breast cancer cells. Genes Dev. 2012;26:1972\u201383.","journal-title":"Genes Dev"},{"key":"2701_CR50","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-7493-1_12","volume":"1711","author":"B Chen","year":"2018","unstructured":"Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling Tumor Infiltrating Immune Cells with CIBERSORT. Methods Mol Biol. 2018;1711:243\u201359.","journal-title":"Methods Mol Biol"},{"key":"2701_CR51","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.","journal-title":"Nat Commun"},{"key":"2701_CR52","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.breast.2023.03.014","volume":"69","author":"L Licata","year":"2023","unstructured":"Licata L, Mariani M, Rossari F, Viale G, Notini G, Naldini MM, et al. Tissue- and liquid biopsy-based biomarkers for immunotherapy in breast cancer. Breast. 2023;69:330\u201341.","journal-title":"Breast"},{"key":"2701_CR53","doi-asserted-by":"publisher","first-page":"101621","DOI":"10.1016\/j.xcrm.2024.101621","volume":"5","author":"H Yamaguchi","year":"2024","unstructured":"Yamaguchi H, Hsu JM, Sun L, Wang SC, Hung MC. Advances and prospects of biomarkers for immune checkpoint inhibitors. Cell Rep Med. 2024;5:101621.","journal-title":"Cell Rep Med"},{"key":"2701_CR54","doi-asserted-by":"publisher","first-page":"582863","DOI":"10.3389\/fonc.2020.582863","volume":"10","author":"C Shuai","year":"2020","unstructured":"Shuai C, Yang X, Pan H, Han W. Estrogen Receptor Downregulates Expression of PD-1\/PD-L1 and Infiltration of CD8(+) T Cells by Inhibiting IL-17 Signaling Transduction in Breast Cancer. Front Oncol. 2020;10:582863.","journal-title":"Front Oncol"},{"key":"2701_CR55","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","volume":"75","author":"MW Teng","year":"2015","unstructured":"Teng MW, Ngiow SF, Ribas A, Smyth MJ. Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res. 2015;75:2139\u201345.","journal-title":"Cancer Res"},{"key":"2701_CR56","doi-asserted-by":"crossref","unstructured":"Jiang Z, Lim SO, Yan M, Hsu JL, Yao J, Wei Y et al. TYRO3 induces anti-PD-1\/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis. J Clin Invest 2021;131.","DOI":"10.1172\/JCI139434"},{"key":"2701_CR57","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554:544\u20138.","journal-title":"Nature"},{"key":"2701_CR58","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017;168:707\u201323.","journal-title":"Cell"},{"key":"2701_CR59","doi-asserted-by":"publisher","first-page":"e280","DOI":"10.1038\/oncsis.2016.70","volume":"5","author":"M Tanikawa","year":"2016","unstructured":"Tanikawa M, Sanjiv K, Helleday T, Herr P, Mortusewicz O. The spliceosome U2 snRNP factors promote genome stability through distinct mechanisms; transcription of repair factors and R-loop processing. Oncogenesis. 2016;5:e280.","journal-title":"Oncogenesis"},{"key":"2701_CR60","doi-asserted-by":"publisher","first-page":"5428","DOI":"10.1016\/j.csbj.2021.09.029","volume":"19","author":"Z Chen","year":"2021","unstructured":"Chen Z, Chen C, Li L, Zhang T, Wang X. The spliceosome pathway activity correlates with reduced anti-tumor immunity and immunotherapy response, and unfavorable clinical outcomes in pan-cancer. Comput Struct Biotechnol J. 2021;19:5428\u201342.","journal-title":"Comput Struct Biotechnol J"},{"key":"2701_CR61","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.1016\/j.csbj.2021.07.014","volume":"19","author":"B Gyorffy","year":"2021","unstructured":"Gyorffy B. Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer. Comput Struct Biotechnol J. 2021;19:4101\u20139.","journal-title":"Comput Struct Biotechnol J"},{"key":"2701_CR62","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.18632\/oncotarget.27215","volume":"10","author":"E Koedoot","year":"2019","unstructured":"Koedoot E, Wolters L, van de Water B, Devedec SEL. Splicing regulatory factors in breast cancer hallmarks and disease progression. Oncotarget. 2019;10:6021\u201337.","journal-title":"Oncotarget"},{"key":"2701_CR63","doi-asserted-by":"publisher","first-page":"x3","DOI":"10.1093\/annonc\/mdz281","volume":"30","author":"N Vasan","year":"2019","unstructured":"Vasan N, Toska E, Scaltriti M. Overview of the relevance of PI3K pathway in HR-positive breast cancer. Ann Oncol. 2019;30:x3\u201311.","journal-title":"Ann Oncol"},{"key":"2701_CR64","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1200\/JCO.2015.65.8013","volume":"34","author":"AH Partridge","year":"2016","unstructured":"Partridge AH, Hughes ME, Warner ET, Ottesen RA, Wong YN, Edge SB, et al. Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival. J Clin Oncol. 2016;34:3308\u201314.","journal-title":"J Clin Oncol"},{"key":"2701_CR65","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1080\/14737140.2021.1944109","volume":"21","author":"K Jhaveri","year":"2021","unstructured":"Jhaveri K, Burris Rd HA, Yap TA, Hamilton E, Rugo HS, Goldman JW, et al. The evolution of cyclin dependent kinase inhibitors in the treatment of cancer. Expert Rev Anticancer Ther. 2021;21:1105\u201324.","journal-title":"Expert Rev Anticancer Ther"},{"key":"2701_CR66","doi-asserted-by":"publisher","first-page":"5734","DOI":"10.1111\/bph.70215","volume":"182","author":"M Posta","year":"2025","unstructured":"Posta M, Gyorffy B. Pathway-level mutational signatures predict breast cancer outcomes and reveal therapeutic targets. Br J Pharmacol. 2025;182:5734\u201347.","journal-title":"Br J Pharmacol"},{"key":"2701_CR67","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.cell.2020.10.003","volume":"183","author":"I Ballesteros","year":"2020","unstructured":"Ballesteros I, Rubio-Ponce A, Genua M, Lusito E, Kwok I, Fernandez-Calvo G, et al. Co-option of Neutrophil Fates by Tissue Environments. Cell. 2020;183:1282\u201397. e18.","journal-title":"Cell"},{"key":"2701_CR68","doi-asserted-by":"crossref","unstructured":"Nojima T, Rebelo K, Gomes T, Grosso AR, Proudfoot NJ, Carmo-Fonseca M. RNA Polymerase II Phosphorylated on CTD Serine 5 Interacts with the Spliceosome during Co-transcriptional Splicing. Mol Cell 2018;72:369\u2009\u2013\u200979 e4.","DOI":"10.1016\/j.molcel.2018.09.004"},{"key":"2701_CR69","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/bioinformatics\/btt703","volume":"30","author":"A Kramer","year":"2014","unstructured":"Kramer A, Green J, Pollard J Jr., Tugendreich S. Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics. 2014;30:523\u201330.","journal-title":"Bioinformatics"},{"key":"2701_CR70","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2701_CR71","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/s43018-022-00438-2","volume":"3","author":"YY Chu","year":"2022","unstructured":"Chu YY, Chen MK, Wei Y, Lee HH, Xia W, Wang YN, et al. Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex. Nat Cancer. 2022;3:1211\u201327.","journal-title":"Nat Cancer"},{"key":"2701_CR72","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1158\/0008-5472.CAN-08-1056","volume":"69","author":"M Narayan","year":"2009","unstructured":"Narayan M, Wilken JA, Harris LN, Baron AT, Kimbler KD, Maihle NJ. Trastuzumab-induced HER reprogramming in resistant breast carcinoma cells. Cancer Res. 2009;69:2191\u20134.","journal-title":"Cancer Res"},{"key":"2701_CR73","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1158\/1535-7163.MCT-21-0098","volume":"21","author":"E Shagisultanova","year":"2022","unstructured":"Shagisultanova E, Crump LS, Borakove M, Hall JK, Rasti AR, Harrison BA, et al. Triple Targeting of Breast Tumors Driven by Hormonal Receptors and HER2. Mol Cancer Ther. 2022;21:48\u201357.","journal-title":"Mol Cancer Ther"},{"key":"2701_CR74","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1158\/1535-7163.MCT-16-0300","volume":"15","author":"P Chen","year":"2016","unstructured":"Chen P, Lee NV, Hu W, Xu M, Ferre RA, Lam H, et al. Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance. Mol Cancer Ther. 2016;15:2273\u201381.","journal-title":"Mol Cancer Ther"},{"key":"2701_CR75","doi-asserted-by":"publisher","first-page":"D512","DOI":"10.1093\/nar\/gku1267","volume":"43","author":"PV Hornbeck","year":"2015","unstructured":"Hornbeck PV, Zhang B, Murray B, Kornhauser JM, Latham V, Skrzypek E. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res. 2015;43:D512\u201320.","journal-title":"Nucleic Acids Res"},{"key":"2701_CR76","doi-asserted-by":"publisher","first-page":"5444","DOI":"10.1038\/s41467-019-13334-8","volume":"10","author":"C Ghezzi","year":"2019","unstructured":"Ghezzi C, Wong A, Chen BY, Ribalet B, Damoiseaux R, Clark PM. A high-throughput screen identifies that CDK7 activates glucose consumption in lung cancer cells. Nat Commun. 2019;10:5444.","journal-title":"Nat Commun"},{"key":"2701_CR77","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/j.annonc.2021.09.015","volume":"32","author":"N Harbeck","year":"2021","unstructured":"Harbeck N, Rastogi P, Martin M, Tolaney SM, Shao ZM, Fasching PA, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol. 2021;32:1571\u201381.","journal-title":"Ann Oncol"},{"key":"2701_CR78","doi-asserted-by":"publisher","first-page":"102697","DOI":"10.1016\/j.dnarep.2019.102697","volume":"82","author":"AS Rajkumar-Calkins","year":"2019","unstructured":"Rajkumar-Calkins AS, Szalat R, Dreze M, Khan I, Frazier Z, Reznichenkov E, et al. Functional profiling of nucleotide Excision repair in breast cancer. DNA Repair (Amst). 2019;82:102697.","journal-title":"DNA Repair (Amst)"},{"key":"2701_CR79","doi-asserted-by":"crossref","unstructured":"Khatpe AS, Adebayo AK, Herodotou CA, Kumar B, Nakshatri H. Nexus between PI3K\/AKT and Estrogen Receptor Signaling in Breast Cancer. Cancers (Basel) 2021;13.","DOI":"10.3390\/cancers13030369"},{"key":"2701_CR80","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1158\/0008-5472.CAN-23-0650","volume":"84","author":"A Soosainathan","year":"2024","unstructured":"Soosainathan A, Iravani M, El-Botty R, Alexander J, Sourd L, Morisset L, et al. Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers. Cancer Res. 2024;84:17\u201325.","journal-title":"Cancer Res"},{"key":"2701_CR81","doi-asserted-by":"publisher","first-page":"e27633","DOI":"10.2196\/27633","volume":"23","author":"A Lanczky","year":"2021","unstructured":"Lanczky A, Gyorffy B. Web-Based Survival Analysis Tool Tailored for Medical Research (KMplot): Development and Implementation. J Med Internet Res. 2021;23:e27633.","journal-title":"J Med Internet Res"},{"key":"2701_CR82","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13073-018-0602-x","volume":"10","author":"W Tang","year":"2018","unstructured":"Tang W, Zhou M, Dorsey TH, Prieto DA, Wang XW, Ruppin E, et al. Integrated proteotranscriptomics of breast cancer reveals globally increased protein-mRNA concordance associated with subtypes and survival. Genome Med. 2018;10:94.","journal-title":"Genome Med"},{"key":"2701_CR83","doi-asserted-by":"publisher","first-page":"105090","DOI":"10.1016\/j.jbc.2023.105090","volume":"299","author":"C Li","year":"2023","unstructured":"Li C, Teng P, Sun S, Cui K, Yao S, Fei B, et al. Acetylation of aldehyde dehydrogenase ALDH1L2 regulates cellular redox balance and the chemosensitivity of colorectal cancer to 5-fluorouracil. J Biol Chem. 2023;299:105090.","journal-title":"J Biol Chem"},{"key":"2701_CR84","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nature15726","volume":"527","author":"E Piskounova","year":"2015","unstructured":"Piskounova E, Agathocleous M, Murphy MM, Hu Z, Huddlestun SE, Zhao Z, et al. Oxidative stress inhibits distant metastasis by human melanoma cells. Nature. 2015;527:186\u201391.","journal-title":"Nature"},{"key":"2701_CR85","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.canlet.2011.09.028","volume":"314","author":"SY Jang","year":"2012","unstructured":"Jang SY, Jang SW, Ko J. Regulation of ADP-ribosylation factor 4 expression by small leucine zipper protein and involvement in breast cancer cell migration. Cancer Lett. 2012;314:185\u201397.","journal-title":"Cancer Lett"},{"key":"2701_CR86","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3892\/ol.2024.14413","volume":"27","author":"L Yang","year":"2024","unstructured":"Yang L, Zhang S, Zheng L, Kong F, Pu P, Li X, et al. Association of ADP\u2013ribosylation factor family genes with prognosis and immune infiltration of breast cancer. Oncol Lett. 2024;27:280.","journal-title":"Oncol Lett"},{"key":"2701_CR87","doi-asserted-by":"publisher","first-page":"110591","DOI":"10.1016\/j.cellsig.2023.110591","volume":"104","author":"A Ali","year":"2023","unstructured":"Ali A, Shafarin J, Muhammad JS, Farhat NM, Hamad M, Soofi A, et al. SCAMP3 promotes breast cancer progression through the c-MYC-beta-Catenin-SQSTM1 growth and stemness axis. Cell Signal. 2023;104:110591.","journal-title":"Cell Signal"},{"key":"2701_CR88","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1001\/jamaoncol.2019.0620","volume":"5","author":"YS Yap","year":"2019","unstructured":"Yap YS, Lu YS, Tamura K, Lee JE, Ko EY, Park YH, et al. Insights Into Breast Cancer in the East vs the West: A Review. JAMA Oncol. 2019;5:1489\u201396.","journal-title":"JAMA Oncol"},{"issue":"Suppl 1","key":"2701_CR89","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.1093\/carcin\/bgv031","volume":"36","author":"SA Langie","year":"2015","unstructured":"Langie SA, Koppen G, Desaulniers D, Al-Mulla F, Al-Temaimi R, Amedei A, et al. Causes of genome instability: the effect of low dose chemical exposures in modern society. Carcinogenesis. 2015;36(Suppl 1):S61\u201388.","journal-title":"Carcinogenesis"},{"issue":"Suppl 1","key":"2701_CR90","doi-asserted-by":"publisher","first-page":"S130","DOI":"10.1093\/toxsci\/kfq371","volume":"120","author":"JA Swenberg","year":"2011","unstructured":"Swenberg JA, Lu K, Moeller BC, Gao L, Upton PB, Nakamura J, et al. Endogenous versus exogenous DNA adducts: their role in carcinogenesis, epidemiology, and risk assessment. Toxicol Sci. 2011;120(Suppl 1):S130\u201345.","journal-title":"Toxicol Sci"},{"key":"2701_CR91","doi-asserted-by":"publisher","first-page":"1253671","DOI":"10.1126\/science.1253671","volume":"348","author":"M Raschle","year":"2015","unstructured":"Raschle M, Smeenk G, Hansen RK, Temu T, Oka Y, Hein MY, et al. DNA repair. Proteomics reveals dynamic assembly of repair complexes during bypass of DNA cross-links. Science. 2015;348:1253671.","journal-title":"Science"},{"key":"2701_CR92","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/s41587-021-00994-5","volume":"39","author":"W Xiao","year":"2021","unstructured":"Xiao W, Ren L, Chen Z, Fang LT, Zhao Y, Lack J, et al. Toward best practice in cancer mutation detection with whole-genome and whole-exome sequencing. Nat Biotechnol. 2021;39:1141\u201350.","journal-title":"Nat Biotechnol"},{"key":"2701_CR93","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","volume":"35","author":"YZ Jiang","year":"2019","unstructured":"Jiang YZ, Ma D, Suo C, Shi J, Xue M, Hu X, et al. Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell. 2019;35:428\u201340. e5.","journal-title":"Cancer Cell"},{"key":"2701_CR94","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/ijc.27767","volume":"132","author":"A Dumay","year":"2013","unstructured":"Dumay A, Feugeas JP, Wittmer E, Lehmann-Che J, Bertheau P, Espie M, et al. Distinct tumor protein p53 mutants in breast cancer subgroups. Int J Cancer. 2013;132:1227\u201331.","journal-title":"Int J Cancer"},{"key":"2701_CR95","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396:1817\u201328.","journal-title":"Lancet"},{"key":"2701_CR96","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMoa2112651","volume":"386","author":"P Schmid","year":"2022","unstructured":"Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kummel S, et al. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med. 2022;386:556\u201367.","journal-title":"N Engl J Med"},{"key":"2701_CR97","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1038\/onc.2008.273","volume":"27","author":"M Campoli","year":"2008","unstructured":"Campoli M, Ferrone S. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene. 2008;27:5869\u201385.","journal-title":"Oncogene"},{"key":"2701_CR98","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41571-019-0266-5","volume":"17","author":"MJ Topper","year":"2020","unstructured":"Topper MJ, Vaz M, Marrone KA, Brahmer JR, Baylin SB. The emerging role of epigenetic therapeutics in immuno-oncology. Nat Rev Clin Oncol. 2020;17:75\u201390.","journal-title":"Nat Rev Clin Oncol"},{"key":"2701_CR99","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1056\/NEJM198608283150906","volume":"315","author":"HO Adami","year":"1986","unstructured":"Adami HO, Malker B, Holmberg L, Persson I, Stone B. The relation between survival and age at diagnosis in breast cancer. N Engl J Med. 1986;315:559\u201363.","journal-title":"N Engl J Med"},{"key":"2701_CR100","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.breast.2021.12.006","volume":"61","author":"HJ Kim","year":"2022","unstructured":"Kim HJ, Kim S, Freedman RA, Partridge AH. The impact of young age at diagnosis (age\u2009<\u200940 years) on prognosis varies by breast cancer subtype: A U.S. SEER database analysis. Breast. 2022;61:77\u201383.","journal-title":"Breast"},{"key":"2701_CR101","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1146\/annurev-med-070909-182917","volume":"62","author":"CK Osborne","year":"2011","unstructured":"Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62:233\u201347.","journal-title":"Annu Rev Med"},{"key":"2701_CR102","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","volume":"34","author":"P Razavi","year":"2018","unstructured":"Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, et al. The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell. 2018;34:427\u201338. e6.","journal-title":"Cancer Cell"},{"key":"2701_CR103","doi-asserted-by":"crossref","unstructured":"Bachelot T, Cottu P, Chabaud S, Dalenc F, Allouache D, Delaloge S et al. Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer. J Clin Oncol 2022:JCO2102179.","DOI":"10.1200\/JCO.21.02179"},{"key":"2701_CR104","doi-asserted-by":"crossref","unstructured":"Chavez-MacGregor M, Miao J, Pusztai L et al. Results from a phase III randomized, placebo-controlled clinical trial evaluating adjuvant endocrine therapy +\/- 1 year of everolimus in patients with high-risk hormone receptor-positive, HER2-negative breast cancer: SWOG S1207., 2022.","DOI":"10.1158\/1538-7445.SABCS22-GS1-07"},{"key":"2701_CR105","doi-asserted-by":"publisher","first-page":"110448","DOI":"10.1016\/j.celrep.2022.110448","volume":"38","author":"ES Knudsen","year":"2022","unstructured":"Knudsen ES, Kumarasamy V, Nambiar R, Pearson JD, Vail P, Rosenheck H, et al. CDK\/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities. Cell Rep. 2022;38:110448.","journal-title":"Cell Rep"},{"key":"2701_CR106","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1200\/JCO.21.02554","volume":"40","author":"M Gnant","year":"2022","unstructured":"Gnant M, Dueck AC, Frantal S, Martin M, Burstein HJ, Greil R, et al. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42\/AFT-05\/BIG-14-03). J Clin Oncol. 2022;40:282\u201393.","journal-title":"J Clin Oncol"},{"key":"2701_CR107","doi-asserted-by":"publisher","first-page":"4444","DOI":"10.1038\/s41467-023-40061-y","volume":"14","author":"RC Coombes","year":"2023","unstructured":"Coombes RC, Howell S, Lord SR, Kenny L, Mansi J, Mitri Z, et al. Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib. Nat Commun. 2023;14:4444.","journal-title":"Nat Commun"},{"key":"2701_CR108","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10549-013-2789-2","volume":"143","author":"S Sengupta","year":"2014","unstructured":"Sengupta S, Biarnes MC, Jordan VC. Cyclin dependent kinase-9 mediated transcriptional de-regulation of cMYC as a critical determinant of endocrine-therapy resistance in breast cancers. Breast Cancer Res Treat. 2014;143:113\u201324.","journal-title":"Breast Cancer Res Treat"},{"key":"2701_CR109","doi-asserted-by":"publisher","first-page":"103863","DOI":"10.1016\/j.breast.2024.103863","volume":"79","author":"L Foffano","year":"2025","unstructured":"Foffano L, Cucciniello L, Nicolo E, Migliaccio I, Noto C, Reduzzi C, et al. Cyclin-dependent kinase 4 and 6 inhibitors (CDK4\/6i): Mechanisms of resistance and where to find them. Breast. 2025;79:103863.","journal-title":"Breast"},{"key":"2701_CR110","first-page":"93","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more personalized approach to cancer staging. CA Cancer J Clin. 2017;67:93\u20139.","journal-title":"CA Cancer J Clin"},{"key":"2701_CR111","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.breast.2011.07.008","volume":"21","author":"S Park","year":"2012","unstructured":"Park S, Koo JS, Kim MS, Park HS, Lee JS, Lee JS, et al. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Breast. 2012;21:50\u20137.","journal-title":"Breast"},{"key":"2701_CR112","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1101\/gr.129684.111","volume":"22","author":"DC Koboldt","year":"2012","unstructured":"Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012;22:568\u201376.","journal-title":"Genome Res"},{"key":"2701_CR113","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1186\/1756-0500-4-394","volume":"4","author":"FH Hsu","year":"2011","unstructured":"Hsu FH, Chen HI, Tsai MH, Lai LC, Huang CC, Tu SH, et al. A model-based circular binary segmentation algorithm for the analysis of array CGH data. BMC Res Notes. 2011;4:394.","journal-title":"BMC Res Notes"},{"key":"2701_CR114","doi-asserted-by":"publisher","first-page":"R41","DOI":"10.1186\/gb-2011-12-4-r41","volume":"12","author":"CH Mermel","year":"2011","unstructured":"Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12:R41.","journal-title":"Genome Biol"},{"key":"2701_CR115","doi-asserted-by":"publisher","first-page":"12016","DOI":"10.1021\/acs.analchem.5b03639","volume":"87","author":"BR Dimayacyac-Esleta","year":"2015","unstructured":"Dimayacyac-Esleta BR, Tsai CF, Kitata RB, Lin PY, Choong WK, Lin TD, et al. Rapid High-pH Reverse Phase StageTip for Sensitive Small-Scale Membrane Proteomic Profiling. Anal Chem. 2015;87:12016\u201323.","journal-title":"Anal Chem"},{"key":"2701_CR116","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nmeth.3901","volume":"13","author":"S Tyanova","year":"2016","unstructured":"Tyanova S, Temu T, Sinitcyn P, Carlson A, Hein MY, Geiger T, et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat Methods. 2016;13:731\u201340.","journal-title":"Nat Methods"},{"key":"2701_CR117","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/bioinformatics\/btq170","volume":"26","author":"MD Wilkerson","year":"2010","unstructured":"Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26:1572\u20133.","journal-title":"Bioinformatics"},{"issue":"Suppl 16","key":"2701_CR118","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1186\/1471-2105-13-S16-S12","volume":"13","author":"J Cox","year":"2012","unstructured":"Cox J, Mann M. 1D and 2D annotation enrichment: a statistical method integrating quantitative proteomics with complementary high-throughput data. BMC Bioinformatics. 2012;13(Suppl 16):S12.","journal-title":"BMC Bioinformatics"},{"key":"2701_CR119","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1038\/nbt.3344","volume":"33","author":"SA Shukla","year":"2015","unstructured":"Shukla SA, Rooney MS, Rajasagi M, Tiao G, Dixon PM, Lawrence MS, et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat Biotechnol. 2015;33:1152\u20138.","journal-title":"Nat Biotechnol"},{"key":"2701_CR120","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1093\/bioinformatics\/btv639","volume":"32","author":"M Andreatta","year":"2016","unstructured":"Andreatta M, Nielsen M. Gapped sequence alignment using artificial neural networks: application to the MHC class I system. Bioinformatics. 2016;32:511\u20137.","journal-title":"Bioinformatics"},{"key":"2701_CR121","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12:453\u20137.","journal-title":"Nat Methods"},{"key":"2701_CR122","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41523-018-0066-6","volume":"4","author":"Z Sztupinszki","year":"2018","unstructured":"Sztupinszki Z, Diossy M, Krzystanek M, Reiniger L, Csabai I, Favero F, et al. Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer. NPJ Breast Cancer. 2018;4:16.","journal-title":"NPJ Breast Cancer"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02701-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02701-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02701-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T13:03:18Z","timestamp":1786453398000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-026-02701-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":122,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2701"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02701-x","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"6 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All participants provided written informed consent in accordance with institutional guidelines and the Declaration of Helsinki. All procedures were approved by the institutional research ethics committees (Application No.: AS-IRB-BM-17056 and 1-106-05-168).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"192"}}